What's breaking now, across thousands of outlets.
Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.
We haven't written up this one. Forbes has the full story — the link below goes straight to it.
Valve’s Steam Business Team took to the stage at the Steam Indie Connect event in Korea and took questions from an audience of game developers.
A sort of review of the benchmarking industry and what's missing.
Announcing Artificial Analysis Intelligence Index v5, featuring 2 new benchmarks and 3 upgrades. For the first time, the majority of the Index is built on private datasets The Artificial Analysis…
A year ago, Endpoints Signal surveyed almost 1,500 biopharma insiders about the very near-term prospects of AI accelerating drug discovery. Scientists, interestingly, were the most skeptical.
Enterprise artificial intelligence context startup Jedify Inc. today formally launched Data Agents, a product that lets business teams set up autonomous AI analysts by describing the work they want…
Anthropic released early results from drug development work with six partners, including Bristol Myers Squibb
